Search Results - "Butler, Madison K"

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition by McNeill, Robert S, Stroobant, Emily E, Smithberger, Erin, Canoutas, Demitra A, Butler, Madison K, Shelton, Abigail K, Patel, Shrey D, Limas, Juanita C, Skinner, Kasey R, Bash, Ryan E, Schmid, Ralf S, Miller, C Ryan

“…Glioblastoma (GBM) is the most common adult primary brain tumor. Multimodal treatment is empiric and prognosis remains poor. Recurrent PIK3CA missense…”
Get full text

Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy by Yu, Guangyang, Butler, Madison K, Abdelmaksoud, Abdalla, Pang, Ying, Su, Yu-Ting, Rae, Zachary, Dadkhah, Kimia, Kelly, Michael C, Song, Young K, Wei, Jun S, Terabe, Masaki, Atony, Ramya, Mentges, Kelly, Theeler, Brett J, Penas-Prado, Marta, Butman, John, Camphausen, Kevin, Zaghloul, Kareem A, Nduom, Edjah, Quezado, Martha, Aldape, Kenneth, Armstrong, Terri S, Gilbert, Mark R, Gulley, James L, Khan, Javed, Wu, Jing

“…Glioma is the most common primary malignant brain tumor with a poor prognosis. Immune checkpoint inhibitors have been of great interest in investigation of…”
Get full text

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas by Wu, Jing, Yuan, Ying, Long Priel, Debra A, Fink, Danielle, Peer, Cody J, Sissung, Tristan M, Su, Yu-Ting, Pang, Ying, Yu, Guangyang, Butler, Madison K, Mendoza, Tito R, Vera, Elizabeth, Ahmad, Salman, Bryla, Christine, Lindsley, Matthew, Grajkowska, Ewa, Mentges, Kelly, Boris, Lisa, Antony, Ramya, Garren, Nancy, Siegel, Christine, Lollo, Nicole, Cordova, Christine, Aboud, Orwa, Theeler, Brett J, Burton, Eric M, Penas-Prado, Marta, Leeper, Heather, Gonzales, Javier, Armstrong, Terri S, Calvo, Katherine R, Figg, William D, Kuhns, Douglas B, Gallin, John I, Gilbert, Mark R

“…To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade…”
Get full text

Abstract 2372: Kinome profiling of non-germline, genetically engineered mouse models of glioblastoma driven by Cdkn2a , Egfr , and/or Pten mutations reveals genotype-dependent kinase targets by Smithberger, Erin, Flores, Alex R., Butler, Madison K., Dhruv, Harshil D., Johnson, Gary L., Berens, Michael E., Furnari, Frank B., Miller, C. Ryan

“…The most attractive target for personalized medicine of glioblastoma (GBM) remains epidermal growth factor receptor (EGFR), due to its frequency in and…”
Get full text

Abstract 3019: Dynamic kinome profiling of EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy by Smithberger, Erin, Shelton, Abigail K., Butler, Madison K., Flores, Alex R., Bash, Ryan E., Angus, Steven P., Sciaky, Noah, Dhruv, Harshil D., Johnson, Gary L., Berens, Michael E., Furnari, Frank B., Miller, C. Ryan

“…Glioblastoma (GBM) is an aggressive brain tumor with few effective treatments. Epidermal growth factor receptor (EGFR) is frequently amplified and mutated in…”
Get full text

Abstract 1857: Glioblastoma growth is suppressed dual inhibition of EGFR and CDK6 kinases by Smithberger, Erin, Shelton, Abigail K., Bash, Ryan E., Butler, Madison K., Flores, Alex R., Stamper, Allie, Angus, Steven P., East, Michael P., Johnson, Gary L., Berens, Michael E., Furnari, Frank B., Miller, Ryan

“…Glioblastoma (GBM) is a malignant brain tumor that has proven difficult to treat, despite expressing promising targets such as EGFRvIII. EGFRvIII, a mutant…”
Get full text